Lilly Says Compounded Tirzepatide With Added Vitamin B12 Contains Impurities. Is It Safe?

Compounded Tirzepatide Plus Vitamin B12 May Contain ‘Impurities’ — What Does That Mean?

Note: Compounded drugs are not approved by the U.S. Food and Drug Administration (FDA) and may carry greater risks than FDA-approved treatments.

Pharmaceutical company Eli Lilly has issued a new warning about copycat compounded versions of its blockbuster GLP-1 tirzepatide drugs Mounjaro and Zepbound, claiming that variations with added vitamin B12 contain “significant” impurities.

The findings come from a preprint study funded by Lilly that has not yet been peer reviewed, meaning the results haven’t been independently evaluated by outside researchers for publication in a medical journal.

In a statement, Lilly said that it has “notified the U.S. Food and Drug Administration (FDA) about these findings and recommends that people using these untested products contact their physicians for advice and discussion on alternative treatment options.”